Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone847-279-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$694.02 million
Profitability
Miscellaneous
Employees2,191
Next Earnings DateN/A
OptionableOptionable
Akorn (NASDAQ:AKRX) Frequently Asked Questions
What is Akorn's stock symbol?
Akorn trades on the NASDAQ under the ticker symbol "AKRX."
How were Akorn's earnings last quarter?
Akorn, Inc. (NASDAQ:AKRX) announced its quarterly earnings results on Thursday, October, 31st. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.06. The firm earned $176.24 million during the quarter, compared to the consensus estimate of $176.15 million. Akorn had a negative net margin of 53.62% and a negative return on equity of 19.95%. The firm's quarterly revenue was up 6.4% on a year-over-year basis. During the same period last year, the firm posted ($0.06) EPS. View Akorn's Earnings History.
What price target have analysts set for AKRX?
4 brokerages have issued twelve-month price targets for Akorn's stock. Their forecasts range from $4.00 to $11.00. On average, they anticipate Akorn's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 79.9% from the stock's current price. View Analyst Price Targets for Akorn.
What is the consensus analysts' recommendation for Akorn?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akorn.
Has Akorn been receiving favorable news coverage?
Media headlines about AKRX stock have been trending extremely negative this week, InfoTrie reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akorn earned a daily sentiment score of -4.6 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Akorn.
Are investors shorting Akorn?
Akorn saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 7,650,000 shares, a decrease of 17.6% from the September 30th total of 9,280,000 shares. Based on an average daily volume of 1,860,000 shares, the days-to-cover ratio is currently 4.1 days. Approximately 8.1% of the company's stock are sold short. View Akorn's Current Options Chain.
Who are some of Akorn's key competitors?
Some companies that are related to Akorn include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR) and Zogenix (ZGNX).
What other stocks do shareholders of Akorn own?
Who are Akorn's key executives?
Akorn's management team includes the folowing people:
- Mr. Duane A. Portwood, Exec. VP & CFO (Age 53)
- Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 54)
- Mr. Jonathan Kafer, Exec. VP & Chief Commercial Officer (Age 56)
- Dr. Bruce Kutinsky, Consultant (Age 53)
- Mr. Douglas S. Boothe, Pres, CEO & Direcor (Age 55)
Who are Akorn's major shareholders?
Akorn's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Mackay Shields LLC (0.57%), Gabelli Funds LLC (0.35%), Gamco Investors INC. ET AL (0.29%), Rhumbline Advisers (0.23%), Assenagon Asset Management S.A. (0.18%) and California Public Employees Retirement System (0.11%). Company insiders that own Akorn stock include Alan D Weinstein, Brian Tambi, John N Kapoor, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.
Which major investors are selling Akorn stock?
AKRX stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., SG Americas Securities LLC, Chicago Equity Partners LLC and Gabelli Funds LLC. View Insider Buying and Selling for Akorn.
Which major investors are buying Akorn stock?
AKRX stock was bought by a variety of institutional investors in the last quarter, including Mackay Shields LLC, Tibra Equities Europe Ltd, State of Alaska Department of Revenue, Nisa Investment Advisors LLC, Gamco Investors INC. ET AL, California Public Employees Retirement System, Rhumbline Advisers and Moors & Cabot Inc.. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.
How do I buy shares of Akorn?
Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Akorn's stock price today?
One share of AKRX stock can currently be purchased for approximately $3.89.
How big of a company is Akorn?
Akorn has a market capitalization of $490.71 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.
What is Akorn's official website?
How can I contact Akorn?
Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]
MarketBeat Community Rating for Akorn (NASDAQ AKRX)
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
